


## Fosun Newsletter

October 2013


## Stock Information

Stock Price (31/10/2013).....HKD 7.45  
 52-week range.....HKD 3.81-7.46  
 Shares (mn shares).....6,422  
 Market Value (HKD bn).....47.84

Fosun Int'l Stock Price (HKD)



RMB (billion)



## The Third Quarter Financial Data of Fosun Pharma

Unit: yuan Currency: RMB

	As of the end of the reporting period	As of the end of the previous year	Change in the reporting period and the previous year-end (%)
<b>Total Assets</b>	27,589,580,696.34	25,507,140,466.01	8.16
<b>Equity attributable to shareholders of the listed company</b>	14,593,258,574.79	13,558,792,587.27	7.63
	From the beginning of 2013 up to the end of this reporting period (January - September)	From the beginning of 2012 up to the end of the reporting period of last year (January - September)	Increase/decrease as compared with the same period last year (%)
<b>Net cash flow from operating activities</b>	467,404,025.74	415,490,491.69	12.49
	From the beginning of 2013 up to the end of this reporting period (January - September)	From the beginning of 2012 up to the end of the reporting period of last year (January - September)	Increase/decrease as compared with the same period last year (%)
<b>Operating income</b>	7,070,780,938.31	5,387,845,935.96	31.24
<b>Net profit attributable to shareholders of the listed Company</b>	1,389,079,631.65	1,093,223,251.90	27.06
<b>Net profit attributable to shareholders of the listed company net of non-recurring gain or loss</b>	770,933,187.12	637,420,180.98	20.95
<b>Weighted average return on net assets (%)</b>	10.14	10.93	Decreased by 0.79 percent point
<b>Basic earnings per stock (yuan / share)</b>	0.62	0.57	8.77
<b>Diluted earnings per share (yuan / share)</b>	0.62	0.57	8.77

## Industrial Operations

## Fosun Pharma

● **Fosun Pharma Introduced U.S. Pure Encapsulations product series, with an aim of tapping the huge potential of China's high-end dietary supplements market**

On 11th October 2013, Fosun Pharma announced a cooperation with a Canadian well-known health care products company Atrium Innovations Inc. ("Atrium") to introduce international top-notch U.S. Pure Encapsulations products series which was acquired by Atrium in 2004 into China, and accelerate the pace of exploring B2B C2S online sales of high-end dietary supplements. Pure Encapsulations, Atrium's high-end dietary supplements, is one of the top brands among global dietary supplements. The product enjoys five core advantages: exquisite raw material, accurate formula, pure ingredient, low allergy, high bioavailability. Pure Encapsulations has been consistently recommended by over 36,000 doctors over the past 20 years, and consumed by US government important officials and professional athletes. The products are well supported by track records and clinical reports.

● **Fosun Pharma sold Intellectual Property**

On 23 October 2013, Chongqing Fochon, an indirect subsidiary of Fosun Pharma, entered into the transfer agreement with SELLAS Clinicals Holding AG (the "Purchaser") pursuant to which Chongqing Fochon agreed to sell and transfer, and the Purchaser agreed to purchase all of Chongqing Fochon's and its wholly owned subsidiaries' right, title and interest in the Intellectual Property and for global rights, except the PRC, in development, commercialization, sales, distribution, license and all other applicable rights in respect of Fotaglipin Benzoate and Pan-HER inhibitors for a consideration of EUR388 million.

● **Guilin Pharma Announced Partnership with IDIS of Britain to benefit more malaria patients.**

On 29th October, 2013, Guilin Pharma announced to start a **pharmaceutical project** cooperation with IDIS of Britain. Severe malaria patients and their doctors outside the malaria-endemic areas can buy live-saving quality-controlled injection of Artesun. Since the product was pre-certificated by the World Health Organization in 2010, Guilin Pharma's injection of Artesun was registered and sold in 32 countries around the world, and entered the malaria-endemic areas through International humanitarian assistance mechanisms.

## Industrial Operations (Cont.)

## Forte

	Attributable Sales GFA (sq.m.)	Attributable Sales Amount (RMB mn)
October 2013	70,295	811
Jan – Oct 2013	748,092	9,732

## Nanjing Nangang

## The Third Quarter Financial Data of Nanjing Nangang

Unit: yuan Currency: RMB

	As of the end of the reporting period	As of the end of the previous year	Change in the reporting period and the previous year-end (%)
Total Assets	36,298,443,787.20	34,218,181,454.96	6.08
Equity attributable to shareholders of the listed company	8,875,873,576.79	8,791,781,764.04	0.96
	From the beginning of 2013 up to the end of this reporting period (January - September)	From the beginning of 2012 up to the end of the reporting period of last year (January - September)	Increase/decrease as compared with the same period last year (%)
Net cash flow from operating activities	1,929,460,153.29	-299,119,065.47	N/A
	From the beginning of 2013 up to the end of this reporting period (January - September)	From the beginning of 2012 up to the end of the reporting period of last year (January - September)	Increase/decrease as compared with the same period last year (%)
Operating income	20,933,888,607.47	25,068,001,824.47	-16.49
Net profit attributable to shareholders of the listed Company	-27,520,381.12	-481,357,243.33	N/A
Net profit attributable to shareholders of the listed company net of non-recurring gain or loss	-106,450,717.22	-559,747,373.13	N/A
Weighted average return on net assets (%)	-0.31	-5.13	N/A
Basic earnings per stock (yuan / share)	-0.0071	-0.1242	N/A
Diluted earnings per share (yuan / share)	-0.0071	-0.1242	N/A

## Insurance

Premium income (thousand RMB)	Yong'an P&C Insurance	Pramerica Fosun Life Insurance
September 2013	685,000	870
Jan – September 2013	5,744,050	10,550


## Investment

## Fosun has entered into an agreement with Kerzner for Atlantis Resort

On 10 October 2013, Fosun International announced that it has entered into an agreement with Kerzner Group, a leading international developer and operator of destination resorts, casinos and luxury hotels for a new, cutting-edge Atlantis resort along the Haitang Bay National Coast. This will be the first Atlantis resort in China and only the third Atlantis worldwide.

## Fosun acquired One Chase Manhattan Plaza

US time 17 October 2013, a wholly owned subsidiary of Fosun International has signed an agreement of sale and purchase with JPMorgan Chase Bank regarding the acquisition of One Chase Manhattan Plaza, which is located at 16-48 Liberty Street, New York, U.S. A. , at a purchase price of USD725,000,000. One Chase Manhattan Plaza is a 60-storey, 2.2 million square foot Grade-A office building with 5 lower levels on a 2.5 acre plaza. Previously, it was the world headquarters of Chase Manhattan Bank.

**The Group**


- Shareholding percentages represent effective equity interests as at 31 Oct 2013.
- As at 31 October, 2013, the Group held 25% equity interest in Yuyuan.
- On 12 September 2012, Jianlong Group completed its acquisition of 80% equity interest in Huaxia Mining and the Group currently holds a 20.6% equity interest in Huaxia Mining through Jianlong Group.
- The Group held 3.57% equity interest in Zhaojin Mining via its subsidiary Fosun Industrial Investment. As Yuyuan, 25% owned associate of the Group, also held a 25.69% equity interest in Zhaojin Mining, the Group held totally 10% effective equity interest in Zhaojin Mining.
- In addition, Pramerica-Fosun China Opportunity Fund held 3.89% in Folli Follie.
- Nanjing Iron & Steel, a subsidiary of us, held Minsheng Bank's A shares representing 0.66% of the total number of A shares. Our Company and its wholly owned subsidiary Topper Link Limited held Minsheng Bank's H shares representing 9.15% of its total number of H shares. Our Company held Minsheng Bank's A shares through its wholly owned subsidiary, Industrial Development, representing 0.35% of the total number of A shares. In addition, Pramerica-Fosun China Opportunity Fund held Minsheng Bank's H shares representing 0.51% of its total number of H shares. The Group directly hold a total shares representing 2.15% of Minsheng Bank's total number shares.
- The Group began to invest the Perfect World since 2012. Based on the latest filing, The Group and its subsidiaries, Peak Reinsurance, held a total of 11.35% equity, and the Company held 6.70% equity.
- The names of the Group's investment projects.
- The Group directly held 50% equity interest while the other 50% were held by Star Capital Fund.
- Shanghai Star Capital Investment Management Co., Ltd., general partner ("GP") of Shanghai Star Capital Equity Investment L.P..
- Tibet Fosun Investment Management Co., Ltd., GP of Fosun Chuanghong Equity Investment Fund Partnership.
- Shanghai Fosun Capital Investment Management Co., Ltd., GP of Fosun Capital Equity Investment Fund Partnership.
- Carlyle-Fosun (Shanghai) Equity Investment and Management Co., Ltd., GP of Fosun-Carlyle (Shanghai) Equity Investment Fund L.P..
- Fosun Equity Investment Ltd., GP of Pramerica-Fosun China Opportunity Fund.

## Contact Us

Fosun International Investor Relations Department  
E-mail: [IR@fosun.com](mailto:IR@fosun.com), Direct Line: (8621) 2315 6838  
Address: No.2, East Fuxing Rd, Shanghai

### Disclaimer

This document herewith includes forward-looking statements. All statements, other than statements of historical facts, that address activities, events or developments that Fosun International Limited and its portfolio companies expect or anticipate will or may occur in the future (including but not limited to projections, targets, estimates and business plans) are forward-looking statements. The company's actual results or developments may differ materially from those indicated by these forward-looking statements as a result of various factors and uncertainties, and other risk and factors beyond our control. In addition, the Company makes the forward-looking statements referred to herein as of today and undertakes no obligation to update these statements.